Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.35 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.34 |
| ▸ | GCG | P01275 | 8/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.30 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720175 | 0.94 | MEN1 (0.34) | RCE1TEAD4GCG | |
| SCHEMBL10249215 | 0.92 | RCE1 (0.32) | RCE1TEAD4 | |
| SCHEMBL720388 | 0.92 | MEN1 (0.35) | RCE1TEAD4 | |
| SCHEMBL10284580 | 0.91 | RCE1 (0.34) | RCE1TEAD4 | |
| SCHEMBL13552382 | 0.91 | RCE1 (0.34) | RCE1TEAD4GCGHPGDAKR1C3 | |
| SCHEMBL721650 | 0.90 | GCG (0.37) | RCE1TEAD4GCGHPGDITGB3 | |
| SCHEMBL719113 | 0.86 | RCE1 (0.46) | RCE1TEAD4HDAC6 | |
| SCHEMBL718447 | 0.86 | GCG (0.46) | GCG | |
| SCHEMBL3400480 | 0.86 | RCE1 (0.45) | RCE1TEAD4GCGHDAC6HPGD | |
| SCHEMBL716365 | 0.83 | NPC1 (0.40) | RCE1TEAD4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | RCE1 2661/4885TEAD4 253/4885GCG 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.